<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01441921</url>
  </required_header>
  <id_info>
    <org_study_id>PV11059S</org_study_id>
    <nct_id>NCT01441921</nct_id>
  </id_info>
  <brief_title>Effect of Pistachio Intake on Insulin Resistance and Type 2 Diabetes Mellitus</brief_title>
  <acronym>EPIRDEM</acronym>
  <official_title>Effect of Pistachio Intake on Insulin Resistance and Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Investigacio Sanitaria Pere Virgili</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Western Pistachio Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Investigacio Sanitaria Pere Virgili</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Chronic intake of pistachios improves glucose metabolism and insulin resistance
      status thus contributing to decrease the risk of type 2 diabetes mellitus and its associated
      abnormalities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In free-living overweight or obese adult with impaired fasting glucose or impaired glucose
      tolerance we will compare the effects of a pistachio-rich diet or a Mediterranean Diet on:

        -  Fasting glucose levels, hemoglobin A1c, insulin, C peptide, HOMA IR, advanced glycation
           end products and soluble receptor of advanced glycation-end products.

        -  Peripheral haemostatic parameters.

        -  Plasma inflammatory markers.

        -  Lymphocyte expression of toll-like receptors, C peptide, resistin and interleukin-6 in
           peripheral leukocytes.

        -  Lymphocyte glucose transport and expression of glucose transporter 4 in peripheral blood
           leukocytes.

        -  Platelet function including platelet number, mean platelet volume, platelet factor 4
           levels and urinary 11-dehydro-thromboxane B2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in circulating levels of glucose and insulin according to the intervention arm</measure>
    <time_frame>Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm</time_frame>
    <description>Measurement of circulating glucose and insulin levels and cellular glucose uptake</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in inflammatory, oxidative and metabolic risk markers related to glucose/insulin metabolism according to the intervention arm</measure>
    <time_frame>Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm</time_frame>
    <description>Cpeptide, resistin, IL-6, IL-18, Ghrelin, leptin, adiponectin, GLP-1 and oxidized LDL will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in haemostatic parameters according to the intervention arm</measure>
    <time_frame>Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm</time_frame>
    <description>Tissue factor, fibrinogen, PAI-1, vWF will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in HL and LDL size according to the intervention arm</measure>
    <time_frame>Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm</time_frame>
    <description>Plasmi lipoprotein size will be measured by polycacrylamide gradient gel electrophoresis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in advanced glycation end products according to the intervention arm</measure>
    <time_frame>Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm</time_frame>
    <description>Advanced glycation end products and soluble receptor of advanced glycation-end produtcs will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in gene expression in the peripheral cells according to the intervention arm</measure>
    <time_frame>Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm</time_frame>
    <description>RNA from peripheral leukocytes will be isolated for the subsequent measurements of changes in gene expression of toll-like receptors, GLUT-4, C-peptide, resistin adn IL-6, and genes involved in telomere maintenance and oxidation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in cellular glucose uptake according to the intervention arm</measure>
    <time_frame>Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm</time_frame>
    <description>Glucose uptake and GLUT4 protein levels will be assessed in peripheral leukocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in platelet function according to the intervention arm</measure>
    <time_frame>Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first and second intervention arm</time_frame>
    <description>Platelet number, mean platelet volume and platelet factor 4 in blood, and urinary levels of 11-dehydro-thromboxane B2 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in telomeric length of leukocytes (LTL)</measure>
    <time_frame>Participants will be followed for 9 months. Measurements will be done before and after 4 months of the first intervention arm. Measurements will be not analysed after the second period due to expected carry-over effect.</time_frame>
    <description>Telomere lenght will be evaluated as a biomarker of biological age and general health status. Telomere attrition may play an important role in the pathogenesis and severity of type 2 diabetes (T2D) increasing the probability of beta-cell senescence, leading to reduced cell mass and decreased insulin secretion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Control diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low-fat normocaloric diet (30% fat, 55% carbohydrates, 15% proteins)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pistachio diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diet supplemented with 2 ounces of pistachio (35% fat, 50% carbohydrates adn 15% protein)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pistachios</intervention_name>
    <description>Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.
Total duration of intervention and follow-up is nine months.</description>
    <arm_group_label>Pistachio diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control diet</intervention_name>
    <description>Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.
Total duration of intervention and follow-up is nine months.</description>
    <arm_group_label>Control diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI less than 35 kg/m2.

          -  Fasting plasma glucose levels between 100 and 125 mg/dl or

          -  Oral glucose tolerance test of 140 to 199 mg/dl.

        Exclusion Criteria:

          -  Diabetes mellitus.

          -  Alcohol, tobacco, or drug abuse.

          -  Significant liver, kidney, thyroid, or other endocrine diseases.

          -  Frequent consumption of nuts or known history of allergy to them.

          -  Use of plant sterol, oral antidiabetic drugs, supplemental use of phyllium, fish oil
             supplements and multivitamins, vitamin E or other antioxidant supplements.

          -  Bad dentures, implying difficulty to chew pistachios.

          -  Being pregnant or wishing to become a pregnant 6 months before or during the study,
             lactating 6wk before or during the study.

          -  Following vegetarian or weight loss diets.

          -  Other medical or social conditions that difficult the compliance to the intervention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Bullo, Dra.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Investigacio Sanitaria Pere Virgili</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Human Nutrition Unit, Faculty of Medicine, Rovira i Virgili University</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43201</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.iispv.cat/</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Hernández-Alonso P, Salas-Salvadó J, Baldrich-Mora M, Mallol R, Correig X, Bulló M. Effect of pistachio consumption on plasma lipoprotein subclasses in pre-diabetic subjects. Nutr Metab Cardiovasc Dis. 2015 Apr;25(4):396-402. doi: 10.1016/j.numecd.2015.01.013. Epub 2015 Feb 7.</citation>
    <PMID>25791863</PMID>
  </reference>
  <results_reference>
    <citation>Hernández-Alonso P, Salas-Salvadó J, Baldrich-Mora M, Juanola-Falgarona M, Bulló M. Beneficial effect of pistachio consumption on glucose metabolism, insulin resistance, inflammation, and related metabolic risk markers: a randomized clinical trial. Diabetes Care. 2014 Nov;37(11):3098-105. doi: 10.2337/dc14-1431. Epub 2014 Aug 14.</citation>
    <PMID>25125505</PMID>
  </results_reference>
  <results_reference>
    <citation>Hernández-Alonso P, Cañueto D, Giardina S, Salas-Salvadó J, Cañellas N, Correig X, Bulló M. Effect of pistachio consumption on the modulation of urinary gut microbiota-related metabolites in prediabetic subjects. J Nutr Biochem. 2017 Jul;45:48-53. doi: 10.1016/j.jnutbio.2017.04.002. Epub 2017 Apr 12.</citation>
    <PMID>28432876</PMID>
  </results_reference>
  <results_reference>
    <citation>Hernández-Alonso P, Giardina S, Salas-Salvadó J, Arcelin P, Bulló M. Chronic pistachio intake modulates circulating microRNAs related to glucose metabolism and insulin resistance in prediabetic subjects. Eur J Nutr. 2017 Sep;56(6):2181-2191. doi: 10.1007/s00394-016-1262-5. Epub 2016 Jul 6.</citation>
    <PMID>27383196</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>September 20, 2011</study_first_submitted>
  <study_first_submitted_qc>September 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2011</study_first_posted>
  <last_update_submitted>February 7, 2019</last_update_submitted>
  <last_update_submitted_qc>February 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut Investigacio Sanitaria Pere Virgili</investigator_affiliation>
    <investigator_full_name>Dra Monica Bullo</investigator_full_name>
    <investigator_title>Principal Investigators</investigator_title>
  </responsible_party>
  <keyword>pistachio intake</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

